Figure S1. Details of TcdA and TcdB antigen expression constructs

| Antigen      | Construct Details |
|--------------|------------------|
| TxA2         | His6 TcdA (1825-2710) |
| TxA4         | His6 Trx 3C Lk2 TcdA (770-2710) |
| TxA4tr       | His6 Trx Th Lk2 TcdA (770-2389) |
| TxAcen       | His6 Trx Th TcdA (542-1850) |
| TxB2         | His6 TcdB (1756-2366) |
| TxB3         | His6 Trx Th TcdB (1139-2366) |
| TxB4         | His10 Lk1 NusA 3C TcdB (767-2366) |
| TxB5         | His6 NusA Th TcdB (543-2366) |
| TxBcen       | His6 Trx Th TcdB (767-1852) |

Expression constructs contained either a 6xhistidine or 10xhistidine purification tag at the N-terminus. Thioredoxin (Trx) or *E. coli* NusA were employed as solubility fusion proteins which were removed via either thrombin (Th) or HRV 3C (3C) cleavage sequences. Linker sequences were also used on some constructs: (LAKE)$_5$, Lk1 and TcdB (amino acid residues 521-541), Lk2.